UK Markets close in 8 hrs 18 mins
  • FTSE 100

    6,333.84
    0.00 (0.00%)
     
  • FTSE 250

    19,582.35
    0.00 (0.00%)
     
  • AIM

    1,035.04
    0.00 (0.00%)
     
  • GBP/EUR

    1.1259
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.3364
    +0.0042 (+0.3167%)
     
  • BTC-GBP

    13,771.71
    +15.20 (+0.11%)
     
  • CMC Crypto 200

    369.34
    +7.91 (+2.19%)
     
  • S&P 500

    3,577.59
    +20.05 (+0.56%)
     
  • DOW

    29,591.27
    +327.79 (+1.12%)
     
  • CRUDE OIL

    43.47
    +0.41 (+0.95%)
     
  • GOLD FUTURES

    1,827.30
    -10.50 (-0.57%)
     
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,551.82
    +65.62 (+0.25%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • CAC 40

    5,492.15
    0.00 (0.00%)
     

Should You Investigate Champions Oncology, Inc. (NASDAQ:CSBR) At US$8.78?

Simply Wall St
·3-min read

While Champions Oncology, Inc. (NASDAQ:CSBR) might not be the most widely known stock at the moment, it saw a significant share price rise of over 20% in the past couple of months on the NASDAQCM. Less-covered, small caps sees more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Today I will analyse the most recent data on Champions Oncology’s outlook and valuation to see if the opportunity still exists.

View our latest analysis for Champions Oncology

What is Champions Oncology worth?

Great news for investors – Champions Oncology is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $12.65, but it is currently trading at US$8.78 on the share market, meaning that there is still an opportunity to buy now. However, given that Champions Oncology’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What does the future of Champions Oncology look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With revenues expected to grow by 57% over the next couple of years, the future seems bright for Champions Oncology. If the level of expenses is able to be maintained, it looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since CSBR is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on CSBR for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy CSBR. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Champions Oncology.

If you are no longer interested in Champions Oncology, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.